Techcyte and ARUP Laboratories partner to deliver AI-based Digital Diagnostics

65

Techcyte, a leading developer of AI-based image analysis solutions for the diagnostics industry, and ARUP Laboratories, a national reference laboratory and worldwide leader in innovative laboratory research and development, have partnered together to develop and commercialize digital diagnostic solutions using artificial intelligence for labs around the world.

Ralph Yarro, CEO of Techcyte, said, “ARUP is one of the most respected reference labs in the United States. Their expertise combined with Techcyte’s deep-learning image analysis platform will revolutionize the way labs perform diagnostic testing.”

Techcyte’s digital diagnostics platform applies the latest in convolutional neural networks to assist ARUP’s staff in delivering fast and accurate results to doctors and patients. The platform supports a wide range of whole slide scanners as well as multiple tests, such as blood differential, cervical cytology, fine needle aspiration, ova and parasites (fecal), urinalysis, and bacteriology.

The collaboration between ARUP and Techcyte will significantly accelerate the number of new test algorithms available to the lab diagnostic market. ARUP’s vast expertise and access to rare samples combined with Techcyte’s data-pipeline and machine-learning experts will produce high-quality algorithms that can be developed quickly and then introduced into the market following thorough testing.

“Our partnership with Techcyte provides us with the tools to remain in the forefront of laboratory medicine. The emphasis on deep learning analytics will help ARUP expand automation efforts, which in turn drives our quality, efficiency, and containment of healthcare costs,” said Sherrie Perkins, CEO of ARUP Laboratories.

Medical labs, hardware manufacturers, hospitals, and clinics will all benefit from Techcyte’s solutions. In 2019, Techcyte will deliver solutions for blood analysis, fecal ova and parasites, cervical cytology and bacteriology. Additional tests will be announced when they are ready for market use.